$Actinogen Medical Ltd(ACW.AU)$: Actinogen gets a speculative buy rating and A$0.09 target price as Bell Potter initiates coverage of the stock. Australian biotech company following promising initial trial results for its lead cognitive-impairment drug candidate. Actinogen's Xanamem inhibits the enzyme that activates cortisol, high levels of which have been linked to diseases including Alzheimer's and major depression. $TPG Telecom Ltd(TPG.AU)$: UBS trim...
Actinogen Medical Ltdに関するコメント
$Actinogen Medical Ltd(ACW.AU)$
Australian biotech company following promising initial trial results for its lead cognitive-impairment drug candidate. Actinogen's Xanamem inhibits the enzyme that activates cortisol, high levels of which have been linked to diseases including Alzheimer's and major depression.
$TPG Telecom Ltd(TPG.AU)$: UBS trim...
まだコメントはありません